Clinical data for Episealer® accepted for presentation at a global scientific congress

Episurf Medical (Nasdaq: EPIS B) today announces that the scientific abstract Patient specific mini-metal implants. The future of cartilage repair for the right patient? by T. Spalding, J. Holz, T. Jung, M. Lind, P. Verdonk, P. Emans and K. Eriksson has been accepted as a poster presentation at the ICRS (International Cartilage Regeneration & Joint Preservation Society) World Congress in Vancouver, Canada, which will take place on October 5 - 8, 2019. The abstract focuses on clinical outcomes for patients in the “gap age”, 35-60 years old, that have undergone treatment of focal chondral defects using the mini-metal implant Episealer®.

The abstract shows excellent early clinical results from the treatment of focal symptomatic cartilage lesions on the femoral condyles or trochlea area of the knee with an individualised metal implant.

"We are happy that the clinical results from the use of Episealer® knee implants will be presented at this very important meeting. The concept of mini implants is generating more and more interest in the industry. As the title says in this case, the Episealer® technology is a treatment alternative for the future and the fact that the patient improvements are being documented and presented is of great importance to us”, says Pål Ryfors, CEO of Episurf Medical.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags:

About Us

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.